Back to search
FDAFDA · Food and drugs·Recall number Z-1842-2025

ABBOTT DIAGNOSTICS ARCH AUSAB ANTI-HBS (100/EA) REAGENT.

Published June 4, 2025 · Recall initiated: April 24, 2025

Summary

FDA records medical device Class II recall Z-1842-2025, published June 4, 2025 and initiated April 24, 2025. Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office; Status: Ongoing; Reported quantity: 4 units; Lot: Catalog No. 01L8227; GTIN: 380740115364; Order No. 46061983. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

transit delays of certain cold chain products due to severe thunderstorms which may caused the products to be stored outside the recommended labeled storage conditions. This failure could increase the probability of an incorrect test result or a delayed test result.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mckesson Medical-Surgical Inc. Corporate Office
Distributor
US Nationwide distribution in the states of AL, AR, IL, KS, MT, NC, NJ, OR, SC, TN & WV.
Lot
Catalog No. 01L8227; GTIN: 380740115364; Order No. 46061983.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was ABBOTT DIAGNOSTICS ARCH AUSAB ANTI-HBS (100/EA) REAGENT. recalled?

Yes. FDA published recall Z-1842-2025 on June 4, 2025. Reported hazard: transit delays of certain cold chain products due to severe thunderstorms which may caused the products to be stored outside the recommended labeled storage conditions. This failure could increase the probability of an incorrect test result or a delayed test result.

What should I do if I have this product?

Voluntary: Firm initiated · Letter